Arthur E. Schwarting Symposium LIVE Event 2026 – TBD

The Arthur E. Schwarting Symposium is an educational conference focused on pharmacy practice for pharmacists in many settings.

Arthur E. Schwarting Symposium 2026

Five hours of live CE

2025 Schwarting Agenda

11:00am-12:00 pm Information overload to action: Decoding academic concepts for pharmacy preceptors
Jennifer Luciano, PharmD, Director Office of Experiential Education, University of Connecticut School of Pharmacy, Storrs, CT

At the end of this presentation the learner will:

Discuss how ACPE standards, the NAPLEX blueprint, and Entrustable Professional Activities (EPAs) guide the development of clinical competence in students, specifically in the context of patient care.
Describe the Pharmacist Patient Care Process (PPCP) and its key components.
Explain how the PPCP framework is applied in experiential education and clinical rotations.

ACPE UAN: 0009-0000-25-026-L04-P Application

12:05-1:05 pm Patient Safety: Anticoagulation Stewardship: Identifying Key Data, Avoiding Errors, and Enhancing Safety
Youssef Bessada, PharmD, BCPS, BCPP, Assistant Clinical Professor,UConn School of Pharmacy, Storrs, CT

At the end of this presentation the learner will:

Differentiate high-priority, practice-changing information from less relevant or conflicting data after reviewing the anticoagulation guidelines, literature and clinical updates.
Recognize common anticoagulation-related errors in pharmacy practice and implement strategies to minimize patient safety risks
Identify red flag situations in anticoagulation management that pose patient safety risks.
Determine the appropriate guidelines or evidence-based resources to guide clinical decision-making and referrals

ACPE UAN: 0009-0000-25-029-L05-P Application

1:10-2:10 pm Information Overload in Chronic Coronary Disease
Michael White, PharmD, FCCP, FCP, BOT Distinguished Professor and Chair of Pharmacy Practice University of Connecticut School of Pharmacy, Storrs, CT

At the end of this presentation the learner will:

Determine if a patient has chronic cardiac disease (CCD).
Identify lifestyle modifications that can reduce the risk of CCD.
Identify therapies that can reduce final health outcomes for specific CCD patient types to design successful drug regimens.
Describe how the steps in the PPCP process can be applied when reviewing a cardiac patient.

ACPE UAN: 0009-0000-25-028-L01-P Application

2:15-3:15 pm Law: Understanding Disabled Pharmacy Patients’ Right to Nondiscrimination
Caroline Wick, JD, MSPH, BA, Practitioner-in-Residence and Acting Director of the Disability Rights Law Clinic, American University Washington College of Law, Washington DC

At the end of this presentation the learner will:

Describe the federal and state laws that protect patients with disabilities
Recognize situations in which accommodations should be provided to disabled patients
Recall examples of common modifications for patients with disabilities

ACPE UAN: 0009-0000-25-027-L03-P Knowledge

3:20-4:20 pm- So Much STI Data: Information to help you stay current and informed
Jennifer Girotto, PharmD, BCPPS, BCIDP, Associate Clinical Professor, UConn School of Pharmacy, Storrs, CT

At the end of this presentation the learner will

Describe updated screening recommendations and epidemiological trends of sexually transmitted infections (STIs).
Review the Centers for Disease Control and Prevention’s STIs recommendations.
Explain latest evidence based STI updates.
Given medication shortages, outline the pharmacist’s role in delivering targeted patient education and implementing strategies for responsible medication stewardship for STIs.

ACPE UAN: 0009-0000-25-030-L01-P Application

Handouts will be posted 72 hours prior to the event in 2 slide/page and 6 slide/page below:

11:00am-12:00 pm Information overload to action: Decoding academic concepts for pharmacy preceptors 2 slides/page
Information overload to action: Decoding academic concepts for pharmacy preceptors 6 slides/page

12:05-1:05 pm Patient Safety: Anticoagulation Stewardship: Identifying Key Data, Avoiding Errors, and Enhancing Safety 2 slides/page
Patient Safety: Anticoagulation Stewardship: Identifying Key Data, Avoiding Errors, and Enhancing Safety 6 slides/page

1:10-2:10 pm Information Overload in Chronic Coronary Disease – 2 slides/page
Information Overload in Chronic Coronary Disease – 6 slides/page

2:15-3:15 pm Law: Understanding Disabled Pharmacy Patients’ Right to Nondiscrimination 2 slides/page
Law: Understanding Disabled Pharmacy Patients’ Right to Nondiscrimination 6 slides/page

3:20-4:20 pm So Much STI Data: Information to help you stay current and informed – 2 slides/page
So Much STI Data: Information to help you stay current and informed – 6 slides/page

“The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.”

Henry A. Palmer CE Finale LIVE Event Friday, Dec 19, 2025

Photograph of Henry A. Palmer

The School of Pharmacy Henry A. Palmer CE Finale, named for beloved professor and mentor, Dr. Henry A. Palmer, is a continuing education program offered at the end of each calendar year. Held during December, the program helps pharmacists fulfill their last minute CE requirements. The program is typically not a single theme, but an ala carte program offering a variety of presentations covering contemporary issues in pharmacy practice/therapeutics. Pharmacists may enroll in one or more [up to 8] hours of continuing education.

The University of Connecticut

School of Pharmacy

Presents the

Henry A. Palmer C.E. FINALE 2025

Doppelgangers, Imposters, and New Kids on the Block

A LIVE (both virtual and in-person) application and knowledge-based continuing education activity for practicing pharmacists in all settings

Friday, December 19, 2025

7:30 AM – 5:00 PM Eastern Time
Sheraton Hartford South, Rocky Hill, CT

For a full course description see the Henry A. Palmer CE Finale Brochure 2025 COMING SOON

REGISTRATION COMING SOON

Handouts for CE Finale will be available the first week of December

HANDOUTS FOR CE FINALE 2024 (these will be uploaded as available)

LAW: Medical-Legal Considerations of Aging Patients for Pharmacists-1 slide per page and clickable links

Law: Seniors Self-Diagnosing and Treating: A Brave (and scary) New World-6 per page
Law: Seniors Self-Diagnosing and Treating: A Brave (and scary) New World-2 per page

Balancing Safety and Efficacy: Addressing Medication Dilemmas in Older Adults -6 per page
Balancing Safety and Efficacy: Addressing Medication Dilemmas in Older Adults -2 per page

Immunization: Our Best Shot – Tips and Tools to Vaccinate Older Adults-6 per page
Immunization: Our Best Shot – Tips and Tools to Vaccinate Older Adults–2 per page

Opioids: Impact of Palliative Care on Total Pain in the Older Adult-6 per page
Opioids: Impact of Palliative Care on Total Pain in the Older Adult–2 per page

Patient Safety: Cheers to the Beers: Unpacking the Latest Updates for Safer Prescribing-6 per page
Patient Safety: Cheers to the Beers: Unpacking the Latest Updates for Safer Prescribing-2 per page

Beyond Memory Loss: Mastering the Management of Behavioral Symptoms in Dementia– 6 per page
Beyond Memory Loss: Mastering the Management of Behavioral Symptoms in Dementia–2 per page

LAW: Call 1-800-Get-Cash Fast: Drug-Related Advertisements about Litigation-6 per page
LAW: Call 1-800-Get-Cash Fast: Drug-Related Advertisements about Litigation-2 per page

CE FINALE 2024 SCHEDULE/TOPICS/LEARNING OBJECTIVES

7:30-8:00 a.m. – Registration and Check-In/Sign-In

8:00-8:05 a.m. – Opening Remarks- Philip Hritcko, Dean, School of Pharmacy

8:05-8:10 a.m. – Operational Instructions-Jeannette Y. Wick, Dir. OPPD

8:10-9:10 a.m. – LAW: Medical-Legal Considerations of Aging Patients for Pharmacists
Jennifer A. Osowiecki, RPh, JD, Cox & Osowiecki, LLC, Hartford, CT

At the conclusion of this presentation, pharmacists will be able to:

1. List at least three common medical-legal concerns associated with aging.

2. Identify what constitutes elderly abuse or neglect and describe whether the pharmacist has a reporting obligation.

3. Discuss the likelihood of polypharmacy and measures that pharmacists can employ to facilitate better medication management and compliance for elderly patients and their caregivers.

0009-0000-24-042-L03-P (0.1 CEU or 1 contact hour) (Application-based)

9:15-10:15 a.m. Law: Seniors Self-Diagnosing and Treating: A Brave (and scary) New World

Michael White, PharmD, FCCP, FCP, BOT Distinguished Professor and Chair of Pharmacy Practice, University of Connecticut School of Pharmacy, Storrs, CT

At the conclusion of this presentation, pharmacists will be able to:

Describe the reasons seniors are increasingly diagnosing and treating themselves with therapies
Describe the legal and regulatory pathways that provide seniors access to therapies outside the drug supply chain
Describe the ways that pharmacists can recommend dietary supplements that are free of adulterants and contaminants
Describe the risks associated with self-treatment with dietary supplements, “peptides”, and counterfeit drugs

0009-0000-24-044-L03-P (0.1 CEU or 1 contact hour) (Knowledge-based)

10:20-11:20 a.m. – Balancing Safety and Efficacy: Addressing Medication Dilemmas in Older Adults

Christina Polomoff, PharmD, BCACP, BCGP, FASCP, Population Health Clinical Pharmacist, Associate Clinical Professor, University of Connecticut School of Pharmacy, Storrs, CT

At the conclusion of this presentation, pharmacists will be able to:

Analyze pharmacokinetic and pharmacodynamic changes associated with aging
Identify opportunities for deprescribing and medication management
Use evidence-based tools and strategies to optimize medication regimens, applying deprescribing frameworks and decision aids in real-world geriatric care

0009-0000-24-043-L01-P (0.1 CEU or 1 contact hour) (Application-based)

11:25-12:25 p.m. – Immunization: Our Best Shot – Tips and Tools to Vaccinate Older Adults

At the conclusion of this presentation, pharmacists will be able to

1. RECOGNIZE appropriate vaccine recommendations for the older adult population

2. IDENTIFY potential barriers to vaccinations

3. ANALYZE current methods used to improve vaccination rates

4. DISCUSS ways to improve vaccine compliance in your patient population

0009-0000-24-047-L06-P (0.1 CEU or 1 contact hour) (Application-based)

12:25-12:45 p.m. – BREAK-light snacks will be served.

12:45-1:45 p.m. – Opioids: Impact of Palliative Care on Total Pain in the Older Adult

Megan Mitchell, PharmD, MS, Pharmacy Clinical Coordinator Pain Management and Palliative Care, University of Connecticut Healthcare, Farmington, CT

At the conclusion of this presentation, pharmacists will be able to:

Describe Palliative Care and its importance in the healthcare system today
Define the concept of “total pain” and the importance of whole person care in pain and symptom management
Recognize the physiologic changes that occur with aging and how those impact pain and symptom management
Determine the role of the pharmacist in total pain management in the older adult

0009-0000-24-046-L08-P (0.1 CEU or 1 contact hour) (Application-based)

1:50-2:50 p.m. –Patient Safety: Cheers to the Beers: Unpacking the Latest Updates for Safer Prescribing
Kelsey Giara, PharmD, Freelance Medical Writer, Pelham, NH

At the conclusion of this presentation, pharmacists will be able to:

Review the role of the Beers Criteria in reducing potentially inappropriate medication (PIM) use and enhancing patient safety in older adults
Identify recent updates to the Beers Criteria and their implications for medication management in geriatric care
Apply the updated Beers Criteria to real-world scenarios, optimizing medication selection and minimizing risks in older adult

0009-0000-24-045-L05-P (0.1 CEU or 1 contact hour (application-based)

2:55-3:55 p.m. – Beyond Memory Loss: Mastering the Management of Behavioral Symptoms in Dementia

Kristin Waters, PharmD, BCPS, BCPP, Assistant Clinical Professor, UConn School of Pharmacy, Storrs, CT

At the conclusion of this presentation, pharmacists will be able to:

Identify clinical characteristics of the behavioral symptoms of dementia (BSD) including agitation, psychosis, and sleep disturbances
Discuss medications currently used in the management of BSD along with emerging pharmacologic therapy options
Determine the most appropriate pharmacologic treatment option for a patient with behavioral symptoms of dementia based on patient-specific factors

0009-0000-24-048-L01-P (0.1 CEU or 1 contact hour) (Application-based)

4:00-5:00 p.m. –LAW: Call 1-800-Get-Cash Fast: Drug-Related Advertisements about Litigation
Jeannette Y. Wick, RPh, MBA, Director Office of Professional Pharmacy Development, UConn School of Pharmacy, Storrs, CT

At the conclusion of this presentation, pharmacists will be able to:

Explain common terminology associated with commercials targeting older Americans
Describe legal processes associated with lawsuits generated against companies that make products alleged to cause harm
Discuss generalities in potential lawsuits associated with media promotion campaigns
Identify areas where no information is available to provide good, valid answers for patients who ask questions

0009-0000-24-049-L03-P (0.1 CEU or 1 contact hour) (Application-based)

CE FINALE ENCORE WEBINARS AVAILABLE

If you find you cannot make it to our LIVE EVENT on Friday, December 13^th, you can participate in our ENCORE LIVE WEBINARS that will be streamed on the following dates:

Monday, December 16, 2024 12:00 (Noon) – 1:00 pm – Seniors Self-Diagnosing and Treating: A Brave (and scary) New World
Monday, December 16, 2024 7:00 pm – 8:00 pm – Patient Safety: Cheers to the Beers: Unpacking the Latest Updates for Safer Prescribing
Monday, December 16, 2024 8:10 pm – 9:10 pm – Immunization: Our Best Shot – Tips and Tools to Vaccinate Older Adults
Tuesday, December 17, 2024 12:00 (Noon) – 1:00 pm – Opioids: Impact of Palliative Care on Total Pain in the Older Adult
Tuesday, December 17, 2024 7:00 pm-8:00 pm – LAW: Call 1-800-Get-Cash Fast: Drug-Related Advertisements about Litigation
Wednesday, December 18, 2024 12:00 pm-1:00 pm – Beyond Memory Loss: Mastering the Management of Behavioral Symptoms in Dementia

Registration Information

Online: https://ce.pharmacy.uconn.edu/henry-a-palmer-ce-finale/

A continuous class schedule format will be used. This format does not include breaks but does include a 20 minute lunch period.

Refunds and Cancellations: The registration fee, less a $75 processing fee, is refundable for those who cancel their registration three (3) days prior to the program (by December 10) After that time, no refund is available.

Location: The Henry A. Palmer C.E. Finale will be held both virtually or in-person. You must sign in to the Webex link at the designated time using the link in your confirmation email if you decide to participate virtually.

Continuing Education Units

The University of Connecticut, School of Pharmacy, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Statements of Credit will be awarded at CE Finale based on full sessions attended and completed online evaluations. Pharmacists can earn up to 8 contact hours (0.80 CEU) one of which is a Law credit, and one is an Immunization credit, and two are Patient Safety credits.

Please Note: Pharmacists who wish to receive credit for the presentations MUST ACCURATELY complete the registration and online evaluations within 45 days of the live program (January 27, 2026). Participants are accountable for their own continuing education requirements for license renewal and are required to follow up with heather.kleven@uconn.edu to resolve a discrepancy in a timely manner. PLEASE CHECK YOUR CPE MONITOR PROFILE within 3 days of submission to assure that your credits have been properly uploaded. Requests for exceptions will be handled on a case-by-case basis and may result in denial of credit.

Activity Support: There is no funding for this program.

Guideline-Driven Treatment for Mental Illnesses and Substance Abuse Disorders

Pharmacists possess the training and skills necessary to administer certain long-acting injectable (LAI) medications used in the management of mental illnesses and substance use disorders. Through collaborative practice agreements, pharmacists can administer Long Acting Injectables in almost every state. In some states, including the state of Connecticut, this occurs via collaborative agreements, and necessary injection and disease state training. Administration of these medications by pharmacists can increase accessibility of care for patients.

UConn has developed web-based continuing pharmacy education activity to enhance pharmacists’ skills and help them make sound clinical decisions about long acting injectables administration. This course includes eight hours of CPE (or eight hours of credit), required by the State of Connecticut. Successful completion of these eight hours (with four activities consisting of three hours online pre-requisite work and five hours of LIVE CE) will earn the pharmacist a Certificate in Long-Acting Injectables of Psychotropic Medication.

The three activities below are available separately for $17/hour each, or as pre-requisites for the entire Long-Acting Injectable Psychotropic Medication Pharmacist Certificate Training Program at $299 which includes both the prerequisites and the full day of LIVE training.

At the end of this application-based continuing education activity, the learner will be able to:

Describe first- and second-line treatment options for the following disease states:

· Schizophrenia

· Bipolar disorder

· Alcohol use disorder

· Opioid use disorder

Identify where long-acting injectable medications fit into treatment guidelines for each disorder

Apply clinical treatment guidelines to select optimal pharmacologic treatment for a patient diagnosed with these disorders

If desired, pharmacists can register for the entire Long-Acting Injectable Psychotropic Medication Pharmacist Certificate Training Program

or for the individual activities. The Certificate consists of three activities in our online selection, and a 5 hour LIVE activity.

You may register for individual topics at $17/CE Credit Hour, or for the Entire LAIA Certificate at $299.00 which includes 5 hours of LIVE CE and the 3 online pre-requisites listed below.

You must register for ALL 4 activities to receive the bundled pricing of $299.00

In accordance with the Accreditation Council for Pharmacy Education (ACPE) Criteria for Quality and Interpretive Guidelines, The University of Connecticut School of Pharmacy requires that faculty disclose any relationship that the faculty may have with commercial entities whose products or services may be mentioned in the activity.

Dr. Waters is a consultant with Janssen Pharmaceuticals. She will discuss all drugs without bias. All financial interests with ineligible companies (as noted) have been mitigated.

Long-Acting Injectable Medication Products

At the end of this application-based continuing education activity, the learner will be able to:

Compare and contrast among different long-acting injectable (LAI) medications currently available for the

treatment of schizophrenia, bipolar disorder and substance use disorders including:

· Dosing

· Generic and brand names

· Adverse effects

· Administration schedule

· Overlap with oral medications

· FDA-approved indications

If desired, pharmacists can register for the entire Long-Acting Injectable Psychotropic Medication Pharmacist Certificate Training Program

or for the individual activities. The Certificate consists of three activities in our online selection, and a 5 hour LIVE activity.

You may register for individual topics at $17/CE Credit Hour, or for the Entire LAIA Certificate at $299.00 which includes 5 hours of LIVE CE and the 3 online pre-requisites listed below.

You must register for ALL 4 activities to receive the bundled pricing of $299.00

Dr. Waters is a consultant with Janssen Pharmaceuticals. She will discuss all drugs without bias. All financial interests with ineligible companies (as noted) have been mitigated.

Mental Illness and Substance Use Disorders: Background

If desired, pharmacists can register for the entire Long-Acting Injectable Psychotropic Medication Pharmacist Certificate Training Program

or for the individual activities. The Certificate consists of three activities in our online selection, and a 5 hour LIVE activity.

You may register for individual topics at $17/CE Credit Hour, or for the Entire LAIA Certificate at $299.00 which includes 5 hours of LIVE CE and the 3 online pre-requisites listed below.

You must register for ALL 4 activities to receive the bundled pricing of $299.00

Dr. Waters is a consultant with Janssen Pharmaceuticals. She will discuss all drugs without bias. All financial interests with ineligible companies (as noted) have been mitigated.

Hour 1: Mental Illness and Substance Use Disorders: Background

1. A 38-year-old patient with an unknown psychiatric history is dropped off at the emergency department by police after being found wandering the streets and knocking on doors at random. The patient admits that they believe they are being monitored by the FBI and that “the mafia” wants to recruit them as a spy. The patient is observed having a conversation with themselves while alone in the examination room.

Which of the following positive symptoms is the patient likely experiencing?
A. Psychosis and auditory hallucinations
B. Auditory hallucinations and delusions
C. Delusions and anhedonia
D. Paranoia and agitation

2. Which of the following is the correct term for fixed, false beliefs that patients with schizophrenia may experience?
A. Delusions
B. Hallucinations
C. Disorganized speech
D. Catatonia

3. A patient with schizophrenia has experienced both positive and negative symptoms for several years. They are now presenting with signs of mania, including pressured speech and grandiosity. Which of the following is true?
A. The patient’s diagnosis will likely change to schizoaffective disorder, bipolar type
B. The patient’s diagnosis will likely change to schizoaffective disorder, depressive type
C. The patient will now be diagnosed with schizophrenia and bipolar disorder
D. The patient will now be diagnosed with schizophrenia and major depressive disorder

4. Which of the following is true about bipolar disorder?
A. The most common time that patients are diagnosed is during childhood
B. Most patients are initially diagnosed with schizophrenia
C. It has a higher mortality rate than major depressive disorder
D. Type II bipolar disorder is associated with more severe episodes of mania than type I

5. Most patients with bipolar disorder spend the majority of their time in which mood phase?
A. Mania
B. Depression
C. Hypomania
D. Euthymia

6. A patient with bipolar disorder presents to their outpatient provider and reports that they believe they are on the verge of a “breakthrough” and will soon become a world-famous author once their manuscript is published. They have recently stopped going to work and have been writing “all day and all night” for the past week. They also report spending thousands of dollars on a new computer so that they have “the best equipment” with which to write their manuscript.
Which of the following symptoms of mania is the patient displaying?
A. Grandiosity, decreased need for sleep, increased goal directed activity
B. Flight of ideas, distractibility, grandiosity
C. Disorganized thoughts, decreased need for sleep, flight of ideas
D. Confusion, excessive spending, distractibility

7. Patient NP was diagnosed with bipolar disorder, type II approximately 5 years ago. They have rarely missed work due to hypomanic symptoms, and are generally able to perform all day-to-day activities without impairment. Following a breakup, NP begins to display signs of grandiosity, flight of ideas, decreased sleep, and increased spending. They also begin to hear the voice of their ex-partner telling them that they are worthless.

Which of the following is most appropriate?
A. NP’s diagnosis should be changed to bipolar disorder type I
B. NP’s diagnosis should remain the same
C. NP’s diagnosis should be changed to schizoaffective disorder
D. NP’s diagnosis should be changed to bipolar disorder, mixed type

8. Which of the following is a risk factor for the development of a substance use disorder?
A. Female gender
B. Age > 65 years
C. Co-occurring psychiatric disorder
D. Parenthood

9. Which type of opioid receptor contributes to the stimulation of the dopamine-related reward system?
A. Mu-opioid receptor
B. Kappa-opioid receptor
C. Delta-opioid receptor
D. Beta-opioid receptors

Law: Psychedelic Drugs: Can They Make the “Trip” to the Pharmacy Shelf?-RECORDED WEBINAR

The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Pharmacists and Pharmacy Technicians are eligible to participate in this application-based activity and will receive 1.0 CE Hour for completing the activity (ACPE UAN 0009-0000-22-017-H03-P), passing the quiz with a grade of 70% or better, and completing an online evaluation. Statements of credit are available via the CPE Monitor online system and your participation will be recorded with CPE Monitor within 72 hours of submission.

The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

Schwarting Webinar 2023 Post-Test

1. Review the development of the knowledge of the effects of psychedelic drugs and their potential use in psychiatry, with an emphasis on psilocybin.
2. Characterize the traditional legal classification of psychedelic drugs and modern reconsideration of their legal status.
3. Describe efforts at the state level to expand the medical use of psychedelic drugs.

The tryptamine class of psychedelic drugs (e.g., LSD, psilocybin) produce their psychedelic/therapeutic effects by acting as agonists of a neurotransmitter in the CNS. What is the relevant neurotransmitter system?

Serotonin
Dopamine
Glutamate

The FDA granted “breakthrough therapy” designation to psilocybin for treatment of a specific condition. What condition is it?

Schizophrenia
Treatment resistant depression
Post traumatic stress disorder

Which feature distinguishes a C-I drug from other controlled substances?

High potential for abuse, especially among hi-riskpopulations
Lack of accepted safety for use under medical supervision
No currently accepted medical use in treatment in the United States

Which state was the first to approve the use of psilocybin for medical use?

California
Oregon
Maryland

A patient considering psilocybin treatment for a psychiatric disorder asks you for advice; he is specifically interested in disadvantages of this type of therapy. What do you tell him?

Use of psychedelic therapy is time-and resource-intensive
Requires multiple treatments with a slow onset of activity
There is a high risk of autonomic side effects and addiction

In the state where medical use of psilocybin was first approved, which of the following statements describes its availability?

Psilocybin can be purchased at retail outlets including pharmacies
Psilocybin is available from any therapist throughout the state
Psilocybin is only available in state licensed clinics

Patient Safety: Pharmacy Metrics-Recorded Webinar

The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Pharmacists and Pharmacy Technicians are eligible to participate in this application-based activity and will receive up to 1.0 CE Hours (or 0.1 CEUs) for completing the activity ACPE UAN 0009-0000-23-026-H05-T, passing the quiz with a grade of 70% or better, and completing an online evaluation. Statements of credit are available via the CPE Monitor online system and your participation will be recorded with CPE Monitor within 72 hours of submission.

1. Which of the following is NOT a use for metrics in pharmacies?
A. Quantify workflow
B. Exhaust staff
C. Establish comparators

2. Patient-centered metrics are based on which of the following?
A. Profits
B. Public health initiatives
C. Patient complaints

3. _____ is a metric used to assess productivity.
A. Time-to-fill
B. Rate of medication errors
C. Out-of-stock prescriptions

4. Which of the following is a good way to reach vaccination metrics?
A. Letting the patient contact the pharmacy about vaccinations
B. Reminding patients of vaccinations at the register
C. Relying on advertising to encourage patients

5. What does SMART goals, a great way to develop an approach to improve metrics, stand for?
A. Specific, Measurable, Achievable, Relevant, Time-Bound
B. Specific, Measurable, Achievable, Resourceful, Time-Bound
C. Specific, Measurable, Accurate, Reasonable, Time-Bound

6. What is the most important skill in the workplace when tackling metrics?
A. Speed
B. Communication
C. Knowledge

7. Many metrics focus on efficiency. What other consideration is crucial?
A. Type of pharmacy
B. Patient safety
C. Workload or volume

8. Select the statement that is TRUE:
A. Metrics usually refer to a general aspect of pharmacy tasks, so they are the same in community and clinical settings.
B. While metrics often refer to a general aspect of pharmacy tasks, they can vary greatly between community and clinical settings.
C. While metrics often refer to a general aspect of pharmacy tasks, pharmacies should stay away from standard metrics and develop new approaches.

9. Super Tech is worried about her pharmacy’s time-to-fill metric. Wonder Pharmacist is focused on inventory metrics. Three months go by and they haven’t made good progress on either. Why?
A. They are working alone on each metric, but need to be working together.
B. It’s not possible to work on two metrics at the same time.
C. Improving time-to-fill metrics will adversely influence inventory metrics.

10. Which of the following activity falls heavily on pharmacy technicians and contributes heavily to pharmacy metrics in the community setting?
A. Vaccinations
B. Insurance and billing
C. In-person patient interaction

NAPLEX Calculation Review LIVE Event-2025

Are you studying for the NAPLEX EXAM?

NAPLEX Pharmacy Calculations Review 2025

Live Event-THIS WILL BE A LIVE IN-PERSON Event (no streaming)

Date: Friday, May 16, 2025
Where: Pharmacy Biology Building (PBB) Room 131
Time: 8:30 am – 4:30 pm
Cost: $0

You MUST Register (even though there is no fee)

There is a fee for parking in the North Garage

Typical Schedule:

Friday

8:30-9:00     Check in and Presentation of Program and Review
9:00- 10:00 Diagnostic Test Administration
10:00-10:45 Review Answers t0 Diagnostic Test
10:45-11:00   Break
11:00-12:00   Students work on problem sets
12:00-1:00     Lunch
1:00-4:30       NAPLEX Calculations workshop

Lunch will be provided, please contact Alicia Scolaro at alicia.scolaro@uconn.edu with any dietary restrictions

CT Law Review Handouts

Are you new to Connecticut?

Do you need to take the Connecticut Law Exam for licensure?

Study Guide/Handouts from the 2025 program are now available for $50.

To Order the 2025 Handouts-$50

CT Law Review LIVE Event-2025

Are you new to Connecticut?

Do you need to take the Connecticut Law Exam for licensure?

MPJE CT Law Review 2025

THIS WILL BE both IN PERSON and LIVE STREAMED.

Thursday, May 15, 2025
Time: 8:00 am-5:00 pm
Location: Pharmacy Biology Building Room 131
Cost: $200
There is a fee for parking in the North Garage

REGISTER

Typical Schedule:

8:20-8:30 Check-In
8:30-5:00 Law Review with break for lunch

Lunch will be provided-Please contact Alicia Scolaro at alicia.scolaro@uconn.edu if you have any dietary restrictions.

Click to order 2024 Law Review Handouts

Study Guide/Handouts from the 2025 program will be available for $50.

About this Course

Target Audience

Pharmacist Learning Objectives

Bundle Options

Accreditation Statement

Grant Funding

Requirements for Successful Completion

Faculty

Faculty Disclosure

Disclaimer

Program Content

Program Handouts

Post Test Evaluation

View Questions for Mental Illness and Substance Use Disorders: Background

Additional Courses Available for Long Acting Injectable Training

About this Course

Target Audience

Pharmacist Learning Objectives

Bundle Options

Accreditation Statement

Grant Funding

Requirements for Successful Completion

Faculty

Faculty Disclosure

Disclaimer

Program Content

Program Handouts

Post Test Evaluation

View Questions for Long-Acting Injectable Medication Products

Additional Courses Available for Long Acting Injectable Training

About this Course

Target Audience

Pharmacist Learning Objectives

Bundle Options

Accreditation Statement

Grant Funding

Requirements for Successful Completion

Faculty

Faculty Disclosure

Disclaimer

Program Content

Program Handouts

Post Test Evaluation

View Questions for Mental Illness and Substance Use Disorders: Background

Additional Courses Available for Long Acting Injectable Training

Learning Objectives

Accreditation Statement

Grant Funding

Faculty

Faculty Disclosure

Disclaimer

Content

Handouts

Post Test Pharmacist

About this Course

Learning Objectives

Additional Information

Accreditation Statement

Grant Funding

Faculty

Faculty Disclosure

Disclaimer

Content

Handouts